LU85778A1 - Nouveaux diazepinoindoles,leur preparation et leur utilisation comme medicaments - Google Patents

Nouveaux diazepinoindoles,leur preparation et leur utilisation comme medicaments Download PDF

Info

Publication number: LU85778A1
Authority: LU; Luxembourg
Prior art keywords: compound; acid; addition salt; indole; formula
Prior art date: 1984-02-22

Application number

LU85778A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-02-22

Filing date

1985-02-20

Publication date

1985-12-11

1985-02-20 Application filed by Sandoz Sa filed Critical Sandoz Sa

1985-12-11 Publication of LU85778A1 publication Critical patent/LU85778A1/fr

Links

238000002360 preparation method Methods 0.000 title claims description 11
239000003814 drug Substances 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims description 91
239000002253 acid Substances 0.000 claims description 49
150000003839 salts Chemical class 0.000 claims description 48
229910052739 hydrogen Inorganic materials 0.000 claims description 19
239000001257 hydrogen Substances 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 13
239000012458 free base Substances 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
150000007513 acids Chemical class 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 9
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
230000009467 reduction Effects 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
BSYFXFLGOGQHFU-UHFFFAOYSA-N pyrrolo[2,3-g][1,2]benzodiazepine Chemical class N1=NC=CC=C2C3=NC=CC3=CC=C21 BSYFXFLGOGQHFU-UHFFFAOYSA-N 0.000 claims description 6
125000003342 alkenyl group Chemical group 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
NWSFWEIYXGAMNW-UHFFFAOYSA-N 1h-diazepino[1,7-a]indole Chemical compound N1C=CC=CC2=CC3=CC=CC=C3N12 NWSFWEIYXGAMNW-UHFFFAOYSA-N 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
238000011084 recovery Methods 0.000 claims description 4
230000009466 transformation Effects 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
230000017858 demethylation Effects 0.000 claims description 3
238000010520 demethylation reaction Methods 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
XORPZYQOYUSNCQ-UHFFFAOYSA-N pnu-181731 Chemical compound C1CNCCC2=CC3=CC=CC=C3N21 XORPZYQOYUSNCQ-UHFFFAOYSA-N 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
LSQPJDWFUPVERI-UHFFFAOYSA-N 1,2,3,5-tetrahydro-[1,4]diazepino[1,7-a]indol-4-one Chemical compound C1CNC(=O)CN2C3=CC=CC=C3C=C12 LSQPJDWFUPVERI-UHFFFAOYSA-N 0.000 claims 1
SJJKLOLDEMVAFA-UHFFFAOYSA-N 1,3,4,5-tetrahydro-[1,4]diazepino[1,7-a]indol-2-one Chemical compound C1CNC(=O)CC2=CC3=CC=CC=C3N21 SJJKLOLDEMVAFA-UHFFFAOYSA-N 0.000 claims 1
KWZPKCPGHNCGNE-UHFFFAOYSA-N 5H-[1,4]diazepino[1,7-a]indole Chemical group C1=CN=CCN2C1=CC=1C=CC=CC21 KWZPKCPGHNCGNE-UHFFFAOYSA-N 0.000 claims 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 description 26
239000000243 solution Substances 0.000 description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
238000012360 testing method Methods 0.000 description 13
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
238000002425 crystallisation Methods 0.000 description 8
230000008025 crystallization Effects 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
229950001675 spiperone Drugs 0.000 description 8
206010044565 Tremor Diseases 0.000 description 7
238000003756 stirring Methods 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
-1 diborane Chemical class 0.000 description 6
239000007858 starting material Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
MSVFBWSGQLBKRE-UHFFFAOYSA-N 1,5-dihydroindol-4-one Chemical compound O=C1CC=CC2=C1C=CN2 MSVFBWSGQLBKRE-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000027455 binding Effects 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000012280 lithium aluminium hydride Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000000155 melt Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 2
108091005479 5-HT2 receptors Proteins 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 2
229950001684 cinanserin Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
210000005153 frontal cortex Anatomy 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 2
239000005457 ice water Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960001779 pargyline Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
QUERAHCHJWZYJF-UHFFFAOYSA-N 1-(1h-indol-2-yl)ethanamine Chemical compound C1=CC=C2NC(C(N)C)=CC2=C1 QUERAHCHJWZYJF-UHFFFAOYSA-N 0.000 description 1
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
AYQLHFULDILLPU-UHFFFAOYSA-N 11-phenyl-2,3,4,5-tetrahydro-1h-[1,4]diazepino[1,7-a]indole Chemical compound C12=CC=CC=C2N2CCNCCC2=C1C1=CC=CC=C1 AYQLHFULDILLPU-UHFFFAOYSA-N 0.000 description 1
FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
DVIOTAFMFGEMKY-UHFFFAOYSA-N 3-(cyclopropylmethyl)-11-phenyl-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]indole Chemical compound C1CC2=C(C=3C=CC=CC=3)C3=CC=CC=C3N2CCN1CC1CC1 DVIOTAFMFGEMKY-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WNZTZMZSYKQPMJ-UHFFFAOYSA-N 3-methyl-11-phenyl-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]indole Chemical compound C12=CC=CC=C2N2CCN(C)CCC2=C1C1=CC=CC=C1 WNZTZMZSYKQPMJ-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
IRRSTSKCXGTBGK-UHFFFAOYSA-N N1C=CC(CC=2N1C1=CC=CC=C1C2)=O Chemical compound N1C=CC(CC=2N1C1=CC=CC=C1C2)=O IRRSTSKCXGTBGK-UHFFFAOYSA-N 0.000 description 1
108091002531 OF-1 protein Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001705 anti-serotonergic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
UDYGXWPMSJPFDG-UHFFFAOYSA-M benzyl(tributyl)azanium;bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1 UDYGXWPMSJPFDG-UHFFFAOYSA-M 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
WUQWGLQUIYZDOI-UHFFFAOYSA-N cyclopropanecarboxamide;1h-indole Chemical compound NC(=O)C1CC1.C1=CC=C2NC=CC2=C1 WUQWGLQUIYZDOI-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000010586 diagram Methods 0.000 description 1
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
229910000103 lithium hydride Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000028570 negative regulation of locomotion Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960002888 oxitriptan Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000006349 photocyclization reaction Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000047 product Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000007958 sleep Effects 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920001567 vinyl ester resin Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

LU85778A 1984-02-22 1985-02-20 Nouveaux diazepinoindoles,leur preparation et leur utilisation comme medicaments LU85778A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH86384		1984-02-22
CH86384		1984-02-22

Publications (1)

Publication Number	Publication Date
LU85778A1 true LU85778A1 (fr)	1985-12-11

Family

ID=4196936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85778A LU85778A1 (fr)	1984-02-22	1985-02-20	Nouveaux diazepinoindoles,leur preparation et leur utilisation comme medicaments

Country Status (23)

Country	Link
US (1)	US4673674A (de)
JP (1)	JPS60202887A (de)
AT (1)	AT388379B (de)
BE (1)	BE901725A (de)
CA (1)	CA1271193A (de)
DE (1)	DE3505017A1 (de)
DK (1)	DK78385A (de)
ES (2)	ES8706681A1 (de)
FI (1)	FI79316C (de)
FR (1)	FR2609715B1 (de)
GB (1)	GB2154584B (de)
GR (1)	GR850443B (de)
HU (1)	HU193083B (de)
IL (1)	IL74388A (de)
IT (1)	IT1199949B (de)
LU (1)	LU85778A1 (de)
MY (1)	MY100083A (de)
NL (1)	NL8500370A (de)
PH (1)	PH22247A (de)
PL (2)	PL146274B1 (de)
PT (1)	PT79990B (de)
SE (1)	SE8500822L (de)
ZA (1)	ZA851373B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3635071A1 (de) *	1986-10-15	1988-04-28	Autoflug Gmbh	Rueckenlehnenverriegelung fuer einen mit sicherheitsgurten ausgeruesteten fahrzeugsitz
AU2001243163B2 (en)	2000-03-14	2004-11-04	Pharmacia & Upjohn Company	Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
US9486515B2 (en) *	2005-06-27	2016-11-08	Glaxosmithkline Biologicals S.A.	Immunogenic composition
HU230880B1 (hu) *	2015-04-15	2018-11-29	Richter Gedeon Nyrt	Indol származékok

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1593146A (en) *	1976-11-05	1981-07-15	Beecham Group Ltd	Octahydro-quinolizinyl benzamide derivatives
US4210590A (en) *	1978-01-06	1980-07-01	Mcneil Laboratories, Incorporated	Reduction of indole compounds to indoline compounds
CH649553A5 (de) *	1982-05-06	1985-05-31	Sandoz Ag	Azepinoindole und verfahren zu deren herstellung.

1985
- 1985-02-11 HU HU85510A patent/HU193083B/hu not_active IP Right Cessation
- 1985-02-11 NL NL8500370A patent/NL8500370A/nl not_active Application Discontinuation
- 1985-02-13 BE BE1/11188A patent/BE901725A/fr unknown
- 1985-02-14 PH PH31856A patent/PH22247A/en unknown
- 1985-02-14 DE DE19853505017 patent/DE3505017A1/de not_active Withdrawn
- 1985-02-19 GB GB08504179A patent/GB2154584B/en not_active Expired
- 1985-02-20 GR GR850443A patent/GR850443B/el unknown
- 1985-02-20 ES ES540559A patent/ES8706681A1/es not_active Expired
- 1985-02-20 DK DK78385A patent/DK78385A/da not_active Application Discontinuation
- 1985-02-20 IL IL74388A patent/IL74388A/xx unknown
- 1985-02-20 IT IT47704/85A patent/IT1199949B/it active
- 1985-02-20 SE SE8500822A patent/SE8500822L/xx not_active Application Discontinuation
- 1985-02-20 FI FI850702A patent/FI79316C/fi not_active IP Right Cessation
- 1985-02-20 PT PT79990A patent/PT79990B/pt unknown
- 1985-02-20 LU LU85778A patent/LU85778A1/fr unknown
- 1985-02-21 JP JP60034261A patent/JPS60202887A/ja active Pending
- 1985-02-21 US US06/704,040 patent/US4673674A/en not_active Expired - Fee Related
- 1985-02-21 AT AT0052285A patent/AT388379B/de not_active IP Right Cessation
- 1985-02-21 CA CA000474852A patent/CA1271193A/en not_active Expired - Lifetime
- 1985-02-21 PL PL1985268394A patent/PL146274B1/pl unknown
- 1985-02-21 PL PL1985252065A patent/PL144329B1/pl unknown
- 1985-02-22 ZA ZA851373A patent/ZA851373B/xx unknown
1986
- 1986-05-16 ES ES555042A patent/ES8707204A1/es not_active Expired
1987
- 1987-09-25 MY MYPI87001944A patent/MY100083A/en unknown
- 1987-11-23 FR FR878716324A patent/FR2609715B1/fr not_active Expired

Also Published As

Publication number	Publication date
FR2609715B1 (fr)	1989-05-26
PL146274B1 (en)	1989-01-31
HUT38642A (en)	1986-06-30
PL252065A1 (en)	1985-12-03
GB2154584A (en)	1985-09-11
PT79990B (en)	1987-01-13
DK78385D0 (da)	1985-02-20
HU193083B (en)	1987-08-28
MY100083A (en)	1989-08-18
PL144329B1 (en)	1988-05-31
GR850443B (de)	1985-06-19
IT8547704A0 (it)	1985-02-20
IL74388A (en)	1988-12-30
ES555042A0 (es)	1987-07-16
FI850702L (fi)	1985-08-23
GB8504179D0 (en)	1985-03-20
IT8547704A1 (it)	1986-08-20
FI79316C (fi)	1989-12-11
IT1199949B (it)	1989-01-05
ES8706681A1 (es)	1987-06-16
FI850702A0 (fi)	1985-02-20
AT388379B (de)	1989-06-12
ATA52285A (de)	1988-11-15
PT79990A (en)	1985-03-01
SE8500822L (sv)	1985-08-23
SE8500822D0 (sv)	1985-02-20
US4673674A (en)	1987-06-16
FR2609715A1 (fr)	1988-07-22
DE3505017A1 (de)	1985-08-22
DK78385A (da)	1985-08-23
ES8707204A1 (es)	1987-07-16
ES540559A0 (es)	1987-06-16
FI79316B (fi)	1989-08-31
BE901725A (fr)	1985-08-13
GB2154584B (en)	1987-09-30
IL74388A0 (en)	1985-05-31
CA1271193A (en)	1990-07-03
ZA851373B (en)	1986-09-24
NL8500370A (nl)	1985-09-16
PH22247A (en)	1988-07-01
JPS60202887A (ja)	1985-10-14

Publication	Publication Date	Title
CA1088939A (fr)	1980-11-04	Medicaments derives de l'indole
EP0376849A1 (de)	1990-07-04	2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Anwendung als Arzneimittel und sie enthaltende Zusammensetzungen
EP0667344A1 (de)	1995-08-16	3-Acylamino-5-(polysubstituiertes Phenyl)-1,4-Benzodiazepin-2-one verwendbar als CCK-Rezeptor Agonisten
EP0677042A1 (de)	1995-10-18	Indol-piperazine derivate als selektive ligande der 5 ht1d und 5ht1b receptoren, verwendbar als arzneimittel
JPH05112572A (ja)	1993-05-07	１−（ピリド〔３，４−ｂ〕−１，４−オキサジニル−４−イル）−１Ｈ−インドール類
FR2495153A1 (fr)	1982-06-04	Nouvelles dibenzazepines, leur preparation et leur application comme medicaments
EP0306408A1 (de)	1989-03-08	Imidazo[1,2-b]pyridazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
BE898072A (fr)	1984-04-25	Derives du pyrrole et leur preparation.
FR2526434A1 (fr)	1983-11-10	Nouveaux azepino-indoles, leur preparation et leur utilisation comme medicaments
EP0383690A1 (de)	1990-08-22	Derivate von 2-Amino-pentandicarbonsäure, Verfahren zu deren Herstellung und Zwischenverbindungen, ihre Anwendung als Arzneimittel und diese enthaltende Zusammenstellungen
FR2536398A1 (fr)	1984-05-25	Nouveaux composes heterocycliques
EP0178201B1 (de)	1989-02-01	Furo[3,2-c]pyridinderivate, ihre Herstellung und ihre therapeutische Verwendung
LU85778A1 (fr)	1985-12-11	Nouveaux diazepinoindoles,leur preparation et leur utilisation comme medicaments
EP0747379A1 (de)	1996-12-11	Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
BE898151A (fr)	1984-05-04	Nouveaux dérivés de la quinazoline, leur préparation et leur utilisation comme médicaments.
EP0671173A1 (de)	1995-09-13	Verwendung einer Trizyklischederivat zur Herstellung eines Arzneimittels zur Behandlung der Kognitiven- und Gedächtnisstörungen
EP0035925B1 (de)	1984-12-05	3-Chlorchinolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CA2344108C (fr)	2005-11-29	Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1873139A1 (de)	2008-01-02	Neue Naphtalinderivate, ihr Herstellungsverfahren und die pharmazeutischen Zusammensetzungen, die sie enthalten
EP1256583B1 (de)	2005-08-10	Pyrimidin-4-one Derivate, Verfahren zu ihrer Herstellung and sie enthaltende Zusammensetzungen
LU85941A1 (fr)	1986-01-24	Derives de la naphtoxazine,leur preparation,leur application comme medicaments et compositions pharmaceutiques les contenant
EP0718299A1 (de)	1996-06-26	Trizyklische Oximether, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
NL8603236A (nl)	1987-07-16	Optisch actieve 2-chloor-12-(3-dimethylamino-2-methyl-propyl)-12h-dibenzod,g1,3,6dioxazocinen en een werkwijze voor de bereiding ervan.
CH674008A5 (de)	1990-04-30
EP1119564B1 (de)	2002-12-18	Aryl-4-fluoro-4-(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl-methanone derivate als 5-ht1-rezeptor-agonisten